Total Payments
$215,415
2024 Payments
$9,399
Companies
26
Transactions
145
Payment Breakdown by Category
Consulting$184,406 (85.6%)
Research$19,818 (9.2%)
Other$6,150 (2.9%)
Travel$4,318 (2.0%)
Food & Beverage$723.66 (0.3%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $184,406 | 97 | 85.6% |
| Unspecified | $19,818 | 17 | 9.2% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $6,150 | 1 | 2.9% |
| Travel and Lodging | $4,318 | 13 | 2.0% |
| Food and Beverage | $723.66 | 17 | 0.3% |
Payments by Type
General
$195,597
128 transactions
Research
$19,818
17 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $27,761 | 5 | $0 (2024) |
| Xellia Pharmaceuticals | $20,701 | 5 | $0 (2020) |
| Seqirus USA Inc | $19,276 | 19 | $0 (2022) |
| Novartis Pharma AG | $16,109 | 8 | $0 (2022) |
| SANOFI-AVENTIS U.S. LLC | $15,515 | 8 | $0 (2023) |
| SANOFI US SERVICES INC. | $15,003 | 2 | $0 (2022) |
| Amgen Inc. | $13,905 | 19 | $0 (2021) |
| Vertex Pharmaceuticals Incorporated | $13,823 | 14 | $0 (2022) |
| Mitsubishi Tanabe Pharma Development America, Inc. | $12,750 | 4 | $0 (2021) |
| Teva Pharmaceuticals USA, Inc. | $8,355 | 5 | $0 (2020) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $9,399 | 14 | Merck Sharp & Dohme LLC ($2,441) |
| 2023 | $11,081 | 17 | JAZZ PHARMACEUTICALS INC. ($3,713) |
| 2022 | $47,743 | 29 | SANOFI-AVENTIS U.S. LLC ($12,615) |
| 2021 | $40,866 | 12 | Merck Sharp & Dohme Corporation ($20,809) |
| 2020 | $33,059 | 20 | Xellia Pharmaceuticals ($15,951) |
| 2019 | $30,587 | 20 | SANOFI US SERVICES INC. ($9,563) |
| 2018 | $34,309 | 28 | Amgen Inc. ($12,718) |
| 2017 | $8,370 | 5 | Celgene Corporation ($5,331) |
All Payment Transactions
145 individual payment records from CMS Open Payments — Page 1 of 6
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 11/21/2024 | PFIZER INC. | NURTEC ODT (Drug) | Consulting Fee | Cash or cash equivalent | $625.00 | General |
| Category: PAIN | ||||||
| 10/29/2024 | ABBVIE INC. | SKYRIZI (Biological) | Consulting Fee | Cash or cash equivalent | $625.00 | General |
| Category: IMMUNOLOGY | ||||||
| 10/17/2024 | Sumitomo Pharma America, Inc. | ORGOVYX (Drug) | — | Cash or cash equivalent | $625.00 | Research |
| Study: A PHASE 3B STUDY TO EVALUATE BONE MINERAL DENSITY WITH LONG-TERM USE OF RELUGOLIX COMBINATION TABLET IN WOMEN WITH UTERINE FIBROIDS OR ENDOMETRIOSIS • Category: HORMONE THERAPY | ||||||
| 09/19/2024 | PFIZER INC. | NURTEC ODT (Drug) | Consulting Fee | Cash or cash equivalent | $500.00 | General |
| Category: PAIN | ||||||
| 08/15/2024 | PFIZER INC. | NURTEC ODT (Drug) | Consulting Fee | Cash or cash equivalent | $625.00 | General |
| Category: PAIN | ||||||
| 08/15/2024 | PFIZER INC. | NURTEC ODT (Drug) | Consulting Fee | Cash or cash equivalent | $375.00 | General |
| Category: PAIN | ||||||
| 08/05/2024 | Merck Sharp & Dohme LLC | LAGEVRIO (Biological) | Consulting Fee | Cash or cash equivalent | $2,441.25 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 07/18/2024 | Sumitomo Pharma America, Inc. | ORGOVYX (Drug) | — | Cash or cash equivalent | $250.00 | Research |
| Study: A PHASE 3B STUDY TO EVALUATE BONE MINERAL DENSITY WITH LONG-TERM USE OF RELUGOLIX COMBINATION TABLET IN WOMEN WITH UTERINE FIBROIDS OR ENDOMETRIOSIS • Category: HORMONE THERAPY | ||||||
| 04/18/2024 | HARMONY BIOSCIENCES LLC | WAKIX (Drug) | — | Cash or cash equivalent | $250.00 | Research |
| Study: WAKIX (Pitolisant) Pregnancy Registry: An Observational Study of the Safety of Pitolisant Exposure in Pregnant Women and Their Offspring • Category: Narcoplepsy | ||||||
| 03/25/2024 | Celgene Corporation | — | — | Cash or cash equivalent | $1,025.00 | Research |
| Study: A Study Evaluating the Efficacy and Safety of Mosunetuzumab Plus Lenalidomide in Comparison to Rituximab Plus Lenalidomide in Participants With Relapsed or Refractory Follicular Lymphoma | ||||||
| 03/11/2024 | ABBVIE INC. | SKYRIZI (Biological) | Consulting Fee | Cash or cash equivalent | $625.00 | General |
| Category: IMMUNOLOGY | ||||||
| 02/15/2024 | PFIZER INC. | NURTEC ODT (Drug) | Consulting Fee | Cash or cash equivalent | $250.00 | General |
| Category: PAIN | ||||||
| 01/31/2024 | JAZZ PHARMACEUTICALS INC. | — | Consulting Fee | Cash or cash equivalent | $945.00 | General |
| 01/24/2024 | Chiesi USA, Inc. | JUXTAPID (Drug) | — | Cash or cash equivalent | $238.00 | Research |
| Study: LOWER:LomitapideObservational Worldwide Evaluation Registry (LOWER) • Category: HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA | ||||||
| 12/21/2023 | PFIZER INC. | NURTEC ODT (Drug) | Consulting Fee | Cash or cash equivalent | $750.00 | General |
| Category: PAIN | ||||||
| 12/08/2023 | AbbVie Inc. | — | Consulting Fee | Cash or cash equivalent | $625.00 | General |
| 12/04/2023 | JAZZ PHARMACEUTICALS INC. | JZP-250 | Consulting Fee | Cash or cash equivalent | $337.50 | General |
| 09/18/2023 | BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD. | NURTEC ODT (Drug) | Consulting Fee | Cash or cash equivalent | $250.00 | General |
| Category: PAIN | ||||||
| 07/31/2023 | JAZZ PHARMACEUTICALS INC. | JZP-150 | Consulting Fee | Cash or cash equivalent | $900.00 | General |
| 07/20/2023 | BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD. | NURTEC ODT (Drug) | Consulting Fee | Cash or cash equivalent | $375.00 | General |
| Category: PAIN | ||||||
| 06/30/2023 | JAZZ PHARMACEUTICALS INC. | JZP-150 | Consulting Fee | Cash or cash equivalent | $900.00 | General |
| 06/28/2023 | AbbVie Inc. | SKYRIZI (Biological) | Consulting Fee | Cash or cash equivalent | $625.00 | General |
| Category: IMMUNOLOGY | ||||||
| 06/27/2023 | AbbVie Inc. | SKYRIZI (Biological) | Consulting Fee | Cash or cash equivalent | $625.00 | General |
| Category: IMMUNOLOGY | ||||||
| 04/30/2023 | JAZZ PHARMACEUTICALS INC. | JZP-250 | Consulting Fee | Cash or cash equivalent | $450.00 | General |
| 04/20/2023 | BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD. | NURTEC ODT (Drug) | Consulting Fee | Cash or cash equivalent | $125.00 | General |
| Category: PAIN | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| The Nuvigil (Armodafinil) Tablets [C-IV]/Provigil (Modafinil) Tablets [C-IV] Pregnancy Registry | Teva Pharmaceuticals USA, Inc. | $7,117 | 3 |
| NN9838-4395 | Novo Nordisk AS | $6,050 | 2 |
| LOWER: Lomitapide Observational Worldwide Evaluation Registry | Amryt Pharma Holdings Ltd | $1,838 | 4 |
| VIGABATRIN REMS PROGRAM | Teva Pharmaceuticals USA, Inc. | $1,238 | 2 |
| Erenumab Pregnancy Registry | Amgen Inc. | $1,188 | 1 |
| A Study Evaluating the Efficacy and Safety of Mosunetuzumab Plus Lenalidomide in Comparison to Rituximab Plus Lenalidomide in Participants With Relapsed or Refractory Follicular Lymphoma | Celgene Corporation | $1,025 | 1 |
| A PHASE 3B STUDY TO EVALUATE BONE MINERAL DENSITY WITH LONG-TERM USE OF RELUGOLIX COMBINATION TABLET IN WOMEN WITH UTERINE FIBROIDS OR ENDOMETRIOSIS | Sumitomo Pharma America, Inc. | $875.00 | 2 |
| WAKIX (Pitolisant) Pregnancy Registry: An Observational Study of the Safety of Pitolisant Exposure in Pregnant Women and Their Offspring | HARMONY BIOSCIENCES LLC | $250.00 | 1 |
| LOWER:LomitapideObservational Worldwide Evaluation Registry (LOWER) | Chiesi USA, Inc. | $238.00 | 1 |
About Dr. Anthony Scialli, MD
Dr. Anthony Scialli, MD is a Gynecology healthcare provider based in Washington, District of Columbia. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 05/29/2007. The National Provider Identifier (NPI) number assigned to this provider is 1538360714.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Anthony Scialli, MD has received a total of $215,415 in payments from pharmaceutical and medical device companies, with $9,399 received in 2024. These payments were reported across 145 transactions from 26 companies. The most common payment nature is "Consulting Fee" ($184,406).
Ad
Practice Information
- Specialty Gynecology
- Other Specialties Obstetrics
- Location Washington, DC
- Active Since 05/29/2007
- Last Updated 09/11/2025
- Taxonomy Code 207VG0400X
- Entity Type Individual
- NPI Number 1538360714
Products in Payments
- Vancomycin (Drug) $20,701
- NO PRODUCT DISCUSSED (Drug) $9,563
- FTY720D (Drug) $7,500
- Provigil (Drug) $7,117
- MAKENA (Drug) $6,563
- FLUCELVAX QUADRIVALENT (MULTI-DOSE VIAL) (Biological) $5,857
- GILENYA (Drug) $4,641
- NURTEC ODT (Drug) $4,500
- FTY720D_GILENYA_NEUROSCIENCE (Drug) $3,968
- JZP-150 $2,700
- AFLURIA QUADRIVALENT (Biological) $2,613
- SKYRIZI (Biological) $2,500
- LAGEVRIO (Biological) $2,441
- Juxtapid (Drug) $1,838
- Revlimid (Drug) $1,781
- Vigabatrin (Drug) $1,238
- Aimovig (Biological) $1,188
- Ponvory (Drug) $1,150
- JZP-250 $1,013
- ORILISSA (Drug) $937.50
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Gynecology Doctors in Washington
Dr. Gaby Moawad, Md, MD
Gynecology — Payments: $1.2M
Gynecology $1.2M
Dr. Andrew Goldstein, M.d, M.D
Gynecology — Payments: $87,380
Gynecology $87,380
Dr. Marilyn Jerome, M.d, M.D
Gynecology — Payments: $14,055
Gynecology $14,055
Dr. Cheryl Iglesia, Md, MD
Gynecology — Payments: $10,045
Gynecology $10,045
Maria Vargas, Md, MD
Gynecology — Payments: $4,271
Gynecology $4,271
Dr. George Samman, M.d, M.D
Gynecology — Payments: $2,439
Gynecology $2,439